Oncology Business Management | Specialty

Second-Line Therapies for Patients With mCRC

April 2nd 2013

Determining Optimal Treatments in mCRC

April 2nd 2013

Treatment Sequencing in Metastatic Colorectal Cancer

April 2nd 2013

Treating Unresectable Metastatic Colorectal Cancer

April 2nd 2013

Treating Resectable Metastatic Colorectal Cancer

April 2nd 2013

Exploring the Neoadjuvant Treatment of Rectal Cancer

April 2nd 2013

Understanding the Role of Aspirin in Colorectal Cancer

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part II

April 2nd 2013

Managing Adjuvant Treatment in Colorectal Cancer, Part I

April 2nd 2013

Practice Benchmark Report Offers Hope for Survival of Independent Oncology Practices

March 29th 2013

The narrowing difference between operating cost and total medical revenue has eased, buying some time for practices to adjust their business models and perhaps survive.

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

March 28th 2013

Although it is now standard practice to utilize the second-generation TKIs dasatinib or nilotinib in patients whose CML has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking.

Dr. Gomella on Sequencing Prostate Cancer Therapies

March 25th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

Trials Should Test Combinations, Sequences of Novel Treatments for Prostate Cancer

March 18th 2013

Following the recent flurry of FDA approvals for prostate cancer medications, oncologists are grappling with questions about which combinations or sequences of those therapies might improve outcomes for patients.

The Role of Companion Diagnostic Testing in Payer Decision Making

March 18th 2013

Companion diagnostics can enable significant improvements in safety, efficacy, outcomes, and cost-effectiveness associated with many existing and new therapies.

Novel Compound LDK378 Receives Breakthrough Designation for ALK+ NSCLC

March 15th 2013

The compound LDK378, a highly selective inhibitor of ALK, has been granted "Breakthrough Therapy Designation" by the FDA for the treatment of patients with ALK-positive metastatic non-small cell lung cancer.

Lymphoseek Approved to Help Detect Lymph Nodes in Breast Cancer and Melanoma

March 13th 2013

The FDA approved the radioactive diagnostic imaging agent technetium Tc 99m tilmanocept (Lymphoseek Injection) to identify lymph nodes for potential removal in patients with breast cancer or melanoma.

Dr. Antonarakis on Sequencing ADT and Sipuleucel-T

March 7th 2013

Emmanuel Stylianos Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses a phase II trial evaluating the optimal sequence for sipuleucel-T and ADT in patients with biochemically recurrent prostate cancer.

Sequestration Takes Effect, Imposes Major Cuts to Cancer Research and Care

March 2nd 2013

Two months after temporarily delaying a package of budget cuts and tax increases, federal lawmakers allowed the changes to automatically take effect by failing to agree on an alternative plan.

Dr. Vogelzang on Sequencing Abiraterone and Enzalutamide

March 1st 2013

Nicholas J. Vogelzang, MD, from Comprehensive Cancer Centers of Nevada, discusses sequencing abiraterone acetate and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer.

Regorafenib Approved to Treat GIST

February 25th 2013

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.